Does maximal androgen blockade (MAB) improve survival? A critical appraisal of the evidence.

Abstract

The conflicting data surrounding the benefit of total androgen blockade compared to monotherapy for metastatic prostate cancer is reviewed. The recent Lancet meta-analysis is critically appraised. A sensitivity analysis of the studies is presented.